BreathForDx: Establishing Exhaled Breath Aerosol (XBA) sampling for diagnosis and screening of respiratory infections
- Funded by European Commission
- Total publications:0 publications
Grant number: 101136380
Grant search
Key facts
Disease
COVID-19, UnspecifiedStart & end year
20242028Known Financial Commitments (USD)
$7,290,153.26Funder
European CommissionPrincipal Investigator
Denkinger ClaudiaResearch Location
GermanyLead Research Institution
UNIVERSITATSKLINIKUM HEIDELBERGResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Respiratory infections resulted in >7 million deaths in 2020 and were responsible for 7 of the last 9 pandemics, causing trillions of 'Ǩs in economic losses. Despite the importance of early detection for individual health and pandemic control, flawed sampling methods for respiratory infections limit the impact of highly-sensitive diagnostics. BreathForDx'Äôs will tackle this problem by establishing exhaled breath aerosol (XBA) as an evidence-based, non-invasive sample for simple detection of respiratory infections that can be undertaken at all levels of care. We will achieve this by developing and optimising two innovative, easy-to-use and scalable XBA sampling devices and generating evidence for their use in diagnosis and screening (for early diagnosis and transmission control). We will use different model pathogens that have caused epidemics and pandemics globally 'Äì SARS-CoV-2, influenza, and tuberculosis (TB) 'Äì and we will generate data on the feasibility of multiplex detection of respiratory pathogens in XBA samples, the adaptability to novel pathogens applying viral metagenomics, and point-of-care testing with lateral-flow assays. We will assess the sampling efficiency of the novel devices against a benchmark Respiratory Aerosol Sampling Chamber and evaluate performance, feasibility, and acceptability, in comparison to the current standard of sampling in multi-country clinical studies of diagnosis and screening. Impact and economic modelling will inform the implementation potential of the novel devices for the different use cases and help assess trade-offs. The project will leverage innovation in bioaerosol and material science, as well as the multidisciplinary (including academia, industry and NGOs) consortium'Äôs track record of delivering transformative diagnostic innovation. We envision that a single breath sample enables accessible and accurate detection of highly transmissible respiratory infections, thereby improving both individual and population health.